(2R,4R)-APDC

Pricing Availability   Qty
Description: Highly selective group II agonist
Chemical Name: (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylate
Purity: ≥98% (HPLC)
Datasheet
Citations (8)
Reviews
Literature (4)

Biological Activity for (2R,4R)-APDC

(2R,4R)-APDC is a highly selective and relatively potent group II metabotropic glutamate receptor agonist. EC50 values are 0.4, 0.4, > 100, > 100, > 300 and > 300 μM for human mGlu2, mGlu3, mGlu1, mGlu5, mGlu4 and mGlu7 receptors respectively. Centrally active following systemic administration in vivo.

Licensing Information

Sold with the permission of Eli Lilly and Company

Technical Data for (2R,4R)-APDC

M. Wt 174.16
Formula C6H10N2O4
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 169209-63-6
PubChem ID 5310984
InChI Key XZFMJVJDSYRWDQ-AWFVSMACSA-N
Smiles N[C@]1([C@](O)=O)C[C@H]([C@](O)=O)NC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for (2R,4R)-APDC

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 100

Preparing Stock Solutions for (2R,4R)-APDC

The following data is based on the product molecular weight 174.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 5.74 mL 28.71 mL 57.42 mL
5 mM 1.15 mL 5.74 mL 11.48 mL
10 mM 0.57 mL 2.87 mL 5.74 mL
50 mM 0.11 mL 0.57 mL 1.15 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for (2R,4R)-APDC

Certificate of Analysis / Product Datasheet
Select another batch:

References for (2R,4R)-APDC

References are publications that support the biological activity of the product.

Monn et al (1996) Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. J.Med.Chem. 39 2990 PMID: 8709133

Schoepp et al (1995) Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate. Neuropharmacology 34 843 PMID: 8532165

Schoepp et al (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 1431 PMID: 10530808


If you know of a relevant reference for (2R,4R)-APDC, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Agonists

Keywords: (2R,4R)-APDC, (2R,4R)-APDC supplier, selective, group, II, agonists, Group, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, (Metabotropic), 1208, Tocris Bioscience

8 Citations for (2R,4R)-APDC

Citations are publications that use Tocris products. Selected citations for (2R,4R)-APDC include:

Lee and Sherman (2012) Intrinsic modulators of auditory thalamocortical transmission. Hear Res 287 43 PMID: 22726616

Proudfoot et al (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16 1591 PMID: 16920620

Jiang et al (2006) Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on DArgic neurons through a microtubule-dependent mechanism. J Neurosci 26 4318 PMID: 16624952

Carlton et al (2009) Group II metabotropic glutamate receptor activation on peripheral nociceptors modulates TRPV1 function. J Neurosci 1248 86 PMID: 19026992


Do you know of a great paper that uses (2R,4R)-APDC from Tocris? Please let us know.

Reviews for (2R,4R)-APDC

There are currently no reviews for this product. Be the first to review (2R,4R)-APDC and earn rewards!

Have you used (2R,4R)-APDC?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.